Dr. Shelley Chu

Partner. Menlo Park. Healthcare.

Dr. Shelley Chu, MD, PhD leads Biotech and Life Sciences investing at Lightspeed, bringing more than two decades of investing and operating experience in the biopharmaceutical industry. As co-head of the firm’s Healthcare Sector, which actively invests across Biotech, Healthtech, and Life Sciences, Shelley’s passion is working closely with entrepreneurs to navigate scientific, clinical, regulatory, business development, and commercial hurdles to bring innovative new medicines to market that address significant unmet medical needs. To date, her investments across all stages, from seed to growth, have led to seven New Drug Approvals by the FDA, 12+ drug candidates in active clinical development, and 17 exits through M&As, IPOs, or partnerships, exemplifying her personal mission of _Doing Well by Doing Good_. During her time at Gilead, where Shelley led R&D strategy across all therapeutic areas and business development in immuno-oncology and HBV, three NDAs were approved and launched.

Since joining Lightspeed, Shelley has led the firm’s biotech investments in seed, spin-outs, series A, and crossover investments such as Aidira, Scorpion (acquired by Eli Lilly), and Pheon. She is also a current or former member of the Board of Directors of Alpha-9, Antares, Diagonal, Dren, Enlaza, Odyssey (ODTX), Protego, Seismic, Triana, Zag Bio, IFM (acquired by Bristol Myers Squibb), IFM Tre (acquired by Novartis), IFM Due (partnered with Novartis), IFM Quattro, Tizona Therapeutics (acquired by Gilead Sciences), Trishula Therapeutics (partnered with AbbVie), and SFJ Pharmaceuticals.

Shelley holds an MD and a PhD in Biochemistry and Biophysics from the University of California at San Francisco (UCSF) and a BA in Molecular Biology from Princeton University, where she serves as Co-Chair for Princeton ASC. She is also a member of the Scientific Advisory Board for BioCentury.